Project Grant R01HL175069
Award Date
7/25/24
Completion Date
6/30/28
Dollars Obligated
$635K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $786,188 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to develop a novel biodegradable gene therapy hydrogel delivery system that can downregulate key genes driving intimal hyperplasia and prosthetic bypass graft failure. The project aims to optimize the hydrogel for sustained siRNA delivery, increased arterial adherence, and targeted vascular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $769,789 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) to develop a catheter-injectable, engineered biomaterial for sustained delivery of the protein therapy neuregulin-1 (NRG1) to the myocardium for the treatment of myocardial infarction (MI). The 4-year project aims to: 1) Evaluate a novel hyaluronic acid-based hydrogel formulation with...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $502,294 to Georgia TECH Research Corp to conduct research on engineered biomaterials for promoting lymphatic regeneration in lymphedema. The project aims to integrate advanced biomaterials and targeted delivery of lipid nanoparticles into current lymphedema surgical procedures to augment lymphangiogenesis and enhance lymphedema treatment. Key activities...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This federal Project Grant award from the National Heart Lung and Blood Institute under CFDA 93.837 (Cardiovascular Diseases Research) provides $758,862 to Yale University to develop a multimodality imaging approach to guide the delivery of therapeutic hydrogels to the heart following a myocardial infarction (MI). The project aims to use this image-guided delivery to prevent cardiac remodeling and progression to heart failure post-MI. The research will employ hybrid SPECT/CT imaging to track...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $694,385 Project Grant to the Rector & Visitors of the University of Virginia to develop a method for enhancing the delivery of adeno-associated virus (AAV) gene therapy to the heart. The goal is to improve the efficiency and safety of AAV-based gene therapies for treating cardiovascular diseases by utilizing ultrasound-mediated cavitation of microbubbles to...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $560,000 to Baylor College of Medicine to conduct preclinical testing of a novel "triple gene therapy" approach for treating ischemic heart failure. The key products and services to be delivered under this award are: In the R61 phase, determining the optimal dosage and therapeutic window for a combined therapy involving: 1) induction of cardiomyocyte...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...